Navigation Links
Alzheimer's Drug Discovery Foundation Hosts 10th International Conference on Alzheimer's Drug Discovery - September 14-15
Date:9/1/2009

Latest Trends and Research Released on Alzheimer's Disease by Academic and Biotech Industry Scientists

NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- The 10th International Conference on Alzheimer's Drug Discovery, hosted by the Alzheimer's Drug Discovery Foundation and the only scientific conference focusing solely on the discovery and development of innovative drugs targeting Alzheimer's disease and related dementias, will convene September 14-15, 2009 at the Hyatt Regency in Jersey City, N.J.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090805/DC57332LOGO)

More than 30 leading international experts from academia and early-stage biotechnology companies will present and discuss their most current research. The meeting draws an audience of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases. Because of ADDF's venture philanthropy focus, the conference is also open to business development and licensing professionals, alliance management professionals, venture capitalists, and other investors in biotechnology.

"We are proud to feature the accomplishments of our funded investigators and other researchers working on innovative approaches to drug discovery for Alzheimer's disease and related dementias," says Howard Fillit, MD, Executive Director of Alzheimer's Drug Discovery Foundation. "Our sole focus is accelerating the discovery of effective new treatments for Alzheimer's disease- bridging the gap that currently exists between basic research and later-stage drug development.

The conference program will focus on four major areas of study:

Neuroprotection and Prevention

Chair: Dr. Frank Longo, MD, PhD, Stanford University

Anti-Amyloid and Protein Misfolding

Chair: Michael Wolfe, PhD, Brigham and Women's Hospital

Anti-Tangles and Frontotemporal Dementia

Chair: Jeff Kuret, PhD, Ohio State University

Alternative Strategies: New Targets for Alzheimer's Disease Therapy

Chair: Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

The program will feature two plenary sessions: "Bridging Neurocognitive Aging and Disease Modification," by Michaela Gallagher, PhD, Johns Hopkins; and "TDP-43 as a New Target for Neurodegenerative Disease," by Virginia Lee, PhD, MBA, University of Pennsylvania.

The Alzheimer's Drug Discovery Foundation will also present the 2009 ADDF Young Investigators Scholarships, highly prestigious scholarships recognizing the early research achievements of ten younger scientists from academia.

The 10th International Conference on Alzheimer's Drug Discovery is sponsored by Pfizer Inc.; Elan Pharmaceuticals; Martek Biosciences Corporation; Schering-Plough; Allon Therapeutics, Inc.; JSW Lifesciences; Abbott; The American Journal of Geriatric Pharmacotherapy; Apredica; Intra-Cellular Therapies, Inc.; and Rhenovia Pharma.

For Conference Participants: To view the complete program schedule, to apply to register for the conference, and for information on accommodations, visit www.alzdiscovery.org.

About the Alzheimer's Drug Discovery Foundation

ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 1,600 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than $35 million to fund more than 240 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 12 countries. The ADDF Website carries the latest, vetted news on Alzheimer's disease, updated weekly.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
2. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
3. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
4. Discovery of natural odors could help develop mosquito repellents
5. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
6. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
7. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
8. New method may accelerate drug discovery for difficult diseases like Parkinsons
9. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):